NRROS

Summary

NRROS (negative regulator of reactive oxygen species, HGNC:24613) is a protein-coding gene on chromosome 3q29, encoding Transforming growth factor beta activator LRRC33 (Q86YC3). Key regulator of transforming growth factor beta-1 (TGFB1) specifically required for microglia function in the nervous system.

Enables transforming growth factor beta binding activity. Predicted to be involved in several processes, including microglia development; sequestering of TGFbeta in extracellular matrix; and transforming growth factor beta receptor signaling pathway. Located in cell surface.

Source: NCBI Gene 375387 — RefSeq curated summary.

At a glance

• Gene–disease (curated): seizures, early-onset, with neurodegeneration and brain calcifications (Definitive, ClinGen)
• GWAS associations: 10
• Clinical variants (ClinVar): 139 total — 8 pathogenic, 5 likely-pathogenic
• Phenotypes (HPO): 9
• MANE Select transcript: NM_198565

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24613
Approved symbol	NRROS
Name	negative regulator of reactive oxygen species
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	UNQ3030, ELLP3030, MGC50789, GARPL1
Ensembl gene	ENSG00000174004
Ensembl biotype	protein_coding
OMIM	615322
Entrez	375387

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000328557, ENST00000461791, ENST00000907983

RefSeq mRNA: 1 — MANE Select: NM_198565 NM_198565

CCDS: CCDS3319

Canonical transcript exons

ENST00000328557 — 3 exons

Exon	Start	End
ENSE00001298013	196659752	196662004
ENSE00001939429	196639694	196639875
ENSE00003640068	196654527	196654647

Expression profiles

Bgee: expression breadth ubiquitous, 160 present calls, max score 93.57.

FANTOM5 (CAGE): breadth broad, TPM avg 3.1651 / max 146.8284, expressed in 576 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40739	11.7113	969
40737	2.2172	458
40738	0.9478	372

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	93.57	gold quality
leukocyte	CL:0000738	93.41	gold quality
granulocyte	CL:0000094	92.60	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.67	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.80	gold quality
bone marrow cell	CL:0002092	85.83	gold quality
spleen	UBERON:0002106	82.67	gold quality
blood	UBERON:0000178	82.57	gold quality
mucosa of stomach	UBERON:0001199	81.91	gold quality
bone marrow	UBERON:0002371	79.84	gold quality
vermiform appendix	UBERON:0001154	79.22	gold quality
lymph node	UBERON:0000029	79.03	gold quality
upper lobe of left lung	UBERON:0008952	77.08	gold quality
upper lobe of lung	UBERON:0008948	76.04	gold quality
right coronary artery	UBERON:0001625	75.99	gold quality
subcutaneous adipose tissue	UBERON:0002190	75.69	gold quality
omental fat pad	UBERON:0010414	75.52	gold quality
peritoneum	UBERON:0002358	75.48	gold quality
caecum	UBERON:0001153	75.47	gold quality
adipose tissue of abdominal region	UBERON:0007808	75.02	gold quality
placenta	UBERON:0001987	74.91	gold quality
right lung	UBERON:0002167	74.62	gold quality
apex of heart	UBERON:0002098	74.23	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	73.78	gold quality
adipose tissue	UBERON:0001013	73.58	gold quality
smooth muscle tissue	UBERON:0001135	73.24	gold quality
gall bladder	UBERON:0002110	72.87	gold quality
lower esophagus muscularis layer	UBERON:0035833	72.87	gold quality
lower esophagus	UBERON:0013473	72.79	gold quality
decidua	UBERON:0002450	72.62	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	4.29
E-ANND-3	yes	3.74
E-MTAB-7249	no	1.11

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRF6

miRNA regulators (miRDB)

14 targeting NRROS, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-7112-3P	97.67	68.77	948
HSA-MIR-9851-5P	97.57	67.49	1067
HSA-MIR-3679-5P	94.75	66.46	862

Literature-anchored findings (GeneRIF, showing 7)

• LRRC33 represents the first identified LRR-containing protein that plays a critical role in desensitizing Toll-like receptor (TLR)-mediated innate immune responses. (PMID:23545260)
• results suggest that LRRC33 and TLRs may form a negative-feedback loop, which is important for the maintenance of immune homeostasis. (PMID:24550525)
• LRRC33 co-localizes and forms complex with latent TGF-beta1 protein on the cell surface and intracellularly in these cells. (PMID:31600200)
• A SNP at the rs6583331 locus 3q29 is associated with the susceptibility of vitiligo in the Chinese Han population. The T allele of the locus within the FBXO45-NRROS gene (3q29) was significantly associated with vitiligo (odds ratio = 1.22, 95% confidence interval: 1.10-1.36, p = 0.0001). Association at the genotype level was strong (p = 0.0007). (PMID:31644309)
• Biallelic mutations in NRROS cause an early onset lethal microgliopathy. (PMID:32100099)
• Wild-type and mutant NRROS proteins co-localize with latent TGF-beta1 intracellularly. (PMID:32197075)
• Specificity of TGF-beta1 signal designated by LRRC33 and integrin alphaVbeta8. (PMID:36008481)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	nrros	ENSDARG00000071491
mus_musculus	Nrros	ENSMUSG00000052384
rattus_norvegicus	Nrros	ENSRNOG00000001752

Paralogs (22): IGFALS (ENSG00000099769), TLR8 (ENSG00000101916), LRRC17 (ENSG00000128606), RXFP2 (ENSG00000133105), CD180 (ENSG00000134061), TLR4 (ENSG00000136869), TLR2 (ENSG00000137462), LRRC32 (ENSG00000137507), LRRC3 (ENSG00000160233), LRRC53 (ENSG00000162621), TLR3 (ENSG00000164342), VASN (ENSG00000168140), RXFP1 (ENSG00000171509), TLR10 (ENSG00000174123), TLR1 (ENSG00000174125), TLR6 (ENSG00000174130), LRRC3B (ENSG00000179796), TSKU (ENSG00000182704), TLR5 (ENSG00000187554), TLR7 (ENSG00000196664), LRIT2 (ENSG00000204033), LRRC3C (ENSG00000204913)

Protein

Protein identifiers

Transforming growth factor beta activator LRRC33 — Q86YC3 (reviewed: Q86YC3)

Alternative names: Leucine-rich repeat-containing protein 33, Negative regulator of reactive oxygen species

All UniProt accessions (1): Q86YC3

UniProt curated annotations — full annotation on UniProt →

Function. Key regulator of transforming growth factor beta-1 (TGFB1) specifically required for microglia function in the nervous system. Required for activation of latent TGF-beta-1 in macrophages and microglia: associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGFB1, and regulates integrin-dependent activation of TGF-beta-1. TGF-beta-1 activation mediated by LRRC33/NRROS is highly localized: there is little spreading of TGF-beta-1 activated from one microglial cell to neighboring microglia, suggesting the existence of localized and selective activation of TGF-beta-1 by LRRC33/NRROS. Indirectly plays a role in Toll-like receptor (TLR) signaling: ability to inhibit TLR-mediated NF-kappa-B activation and cytokine production is probably a consequence of its role in TGF-beta-1 signaling.

Subunit / interactions. Interacts with TGFB1; associates via disulfide bonds with the Latency-associated peptide chain (LAP) regulatory chain of TGFB1, leading to regulate activation of TGF-beta-1. Interacts (via LRR repeats) with TLR2, TLR3, TLR4, TLR9 and probably other Toll-like receptors. Interacts with CYBB/NOX2; the interaction is direct.

Subcellular location. Cell membrane. Endoplasmic reticulum membrane.

Tissue specificity. Mainly expressed in cells of hematopoietic origin. Highly expressed in bone marrow, thymus, liver, lung, intestine and spleen. In the brain, highly expressed in microglia.

Disease relevance. Seizures, early-onset, with neurodegeneration and brain calcification (SENEBAC) [MIM:618875] An autosomal recessive neurodegenerative disorder clinically characterized by refractory seizures apparent in the first year of life, mild early developmental delay, and developmental regression after seizure onset. Other features include hypotonia, hyperreflexia, peripheral spasticity, poor eye contact, absent speech, poor head control, and inability to walk. Brain imaging shows reduced white matter volume with delayed myelination, and punctate calcifications. The protein represented in this entry is involved in disease pathogenesis.

Similarity. Belongs to the LRRC32/LRRC33 family.

RefSeq proteins (1): NP_940967* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050328	Dev_Immune_Receptor	Family

Pfam: PF00560, PF13516, PF13855

UniProt features (43 total): repeat 21, glycosylation site 11, topological domain 2, domain 2, disulfide bond 2, sequence variant 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7Y1R	ELECTRON MICROSCOPY	4.01

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86YC3-F1	83.43	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 219, 363

Glycosylation sites (11): 21, 74, 155, 232, 292, 309, 312, 408, 427, 500, 622

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 192 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_NK_CELL_VS_CD11B_DC_DN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_MYELOID_CELL_DEVELOPMENT, GOBP_INFLAMMATORY_RESPONSE, GOBP_GLIAL_CELL_DEVELOPMENT, GOCC_CELL_SURFACE, GOBP_SUPEROXIDE_METABOLIC_PROCESS, GOBP_NEUROGENESIS, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_MAINTENANCE_OF_LOCATION, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, GOBP_EXTRACELLULAR_REGULATION_OF_SIGNAL_TRANSDUCTION

GO Biological Process (5): inflammatory response (GO:0006954), immune response (GO:0006955), transforming growth factor beta receptor signaling pathway (GO:0007179), microglia development (GO:0014005), obsolete sequestering of TGFbeta in extracellular matrix (GO:0035583)

GO Molecular Function (4): transforming growth factor beta binding (GO:0050431), receptor ligand inhibitor activity (GO:0141069), protein binding (GO:0005515), growth factor binding (GO:0019838)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
defense response	1
immune system process	1
response to stimulus	1
cellular response to transforming growth factor beta stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
microglia differentiation	1
glial cell development	1
myeloid cell development	1
growth factor binding	1
cytokine binding	1
receptor ligand activity	1
molecular function inhibitor activity	1
binding	1
protein binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1224 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NRROS	SMCO1	Q147U7	533
NRROS	TGFB1	P01137	513
NRROS	CEP19	Q96LK0	474
NRROS	ZDHHC19	Q8WVZ1	465
NRROS	UBXN7	O94888	438
NRROS	FBXO45	P0C2W1	426
NRROS	WDR53	Q7Z5U6	417
NRROS	TM4SF19	Q96DZ7	410
NRROS	SLAMF8	Q9P0V8	407
NRROS	PCYT1A	P49585	387
NRROS	DYNLT2B	Q8WW35	373
NRROS	CYBB	P04839	370
NRROS	SLC51A	Q86UW1	347
NRROS	PIGZ	Q86VD9	309
NRROS	CD48	P09326	302
NRROS	MGST2	Q99735	302

IntAct

5 interactions, top by confidence:

A	B	Type	Score
NRROS	NDUFA3	psi-mi:“MI:0914”(association)	0.530
NRROS	HS6ST1	psi-mi:“MI:0914”(association)	0.350
CCDC144BP	AOC2	psi-mi:“MI:0914”(association)	0.350
NFATC1	OBSL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): MARK3 (Affinity Capture-MS), MARK2 (Affinity Capture-MS), CNPY3 (Affinity Capture-MS), RTN4RL2 (Affinity Capture-MS), NDST1 (Affinity Capture-MS), CANX (Affinity Capture-MS), LINGO1 (Affinity Capture-MS), TGFB1 (Affinity Capture-MS), ITPRIP (Affinity Capture-MS), NDUFA3 (Affinity Capture-MS), EPHB4 (Affinity Capture-MS), ALG9 (Affinity Capture-MS), SDF2L1 (Affinity Capture-MS), POMT1 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS)

ESM2 similar proteins: A3KNN3, A4IFA6, A6H789, A6H793, A6NDA9, A8WHP9, E7FE13, O08644, O08742, O08770, O14498, O15197, P0C0K6, P0C0K7, P14616, P14617, P21709, P54760, P54761, P59034, P59035, Q149C3, Q3ZBI5, Q5BK65, Q5JZY3, Q5NVQ6, Q5R7M3, Q60750, Q62178, Q64716, Q6GU68, Q6P7C4, Q6PFC5, Q6UY18, Q80ZD5, Q86SJ2, Q86WK7, Q86YC3, Q8BGX3, Q8BMT4

Diamond homologs: G3XA59, Q14392, Q3ZBI5, Q4R8Y9, Q5BK65, Q5RF01, Q6JN46, Q6PEZ8, Q86YC3, Q8BMT4, Q8CBR6, Q965M2, Q9CQ76, Q6P3Y9, Q7TQ62, Q7Z5L7, A8WHP9, P58727, Q6AXL3, Q9MYW3, Q6QMY6, Q5M7S9, O35367, O46379, P23515, D4AC13, F1MT22, O35930, O75473, O77742, P58874, P59383, Q28256, Q38SD2, Q58A48, Q65YW8, Q65Z91, Q6EMK4, Q6R5P0, Q8WUA8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

139 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	8
Likely pathogenic	5
Uncertain significance	99
Likely benign	17
Benign	5

Top pathogenic / likely-pathogenic (13)

Variant ID	HGVS	Classification
1299756	NM_198565.3(NRROS):c.185T>C (p.Leu62Pro)	Pathogenic
1299757	NM_198565.3(NRROS):c.310C>T (p.Gln104Ter)	Pathogenic
873027	NM_198565.3(NRROS):c.1777C>T (p.Gln593Ter)	Pathogenic
873028	NM_198565.3(NRROS):c.29T>C (p.Leu10Pro)	Pathogenic
873029	NM_198565.3(NRROS):c.1257del (p.Gly420fs)	Pathogenic
873031	NM_198565.3(NRROS):c.1644del (p.Thr549fs)	Pathogenic
873032	NM_198565.3(NRROS):c.190del (p.Leu64fs)	Pathogenic
997046	GRCh37/hg19 3q29(chr3:195747856-197387258)	Pathogenic
2431562	NM_198565.3(NRROS):c.719G>A (p.Trp240Ter)	Likely pathogenic
2636607	NM_198565.3(NRROS):c.1117G>T (p.Glu373Ter)	Likely pathogenic
2663752	NM_198565.3(NRROS):c.1816del (p.Ala606fs)	Likely pathogenic
4056677	NM_198565.3(NRROS):c.1699A>T (p.Arg567Ter)	Likely pathogenic
873030	NM_198565.3(NRROS):c.1981del (p.Leu661fs)	Likely pathogenic

SpliceAI

310 predictions. Top by Δscore:

Variant	Effect	Δscore
3:196639873:GCC:G	donor_gain	1.0000
3:196639876:G:GG	donor_gain	1.0000
3:196654521:CCACA:C	acceptor_loss	1.0000
3:196654522:CACA:C	acceptor_loss	1.0000
3:196654524:CAGG:C	acceptor_loss	1.0000
3:196654525:A:AG	acceptor_gain	1.0000
3:196654525:A:G	acceptor_loss	1.0000
3:196654525:AG:A	acceptor_gain	1.0000
3:196654526:G:GA	acceptor_gain	1.0000
3:196654526:GG:G	acceptor_gain	1.0000
3:196654526:GGGC:G	acceptor_gain	1.0000
3:196654526:GGGCT:G	acceptor_gain	1.0000
3:196654644:GTTG:G	donor_gain	1.0000
3:196639871:GAGCC:G	donor_gain	0.9900
3:196639872:AGCC:A	donor_gain	0.9900
3:196639872:AGCCG:A	donor_loss	0.9900
3:196639873:GCCG:G	donor_gain	0.9900
3:196639874:CC:C	donor_gain	0.9900
3:196639875:CG:C	donor_loss	0.9900
3:196639876:G:GA	donor_loss	0.9900
3:196639877:T:TA	donor_loss	0.9900
3:196639878:GAGT:G	donor_loss	0.9900
3:196639879:A:AC	donor_loss	0.9900
3:196639880:G:C	donor_loss	0.9900
3:196654523:ACAG:A	acceptor_gain	0.9900
3:196654525:AGG:A	acceptor_gain	0.9900
3:196654526:GGG:G	acceptor_gain	0.9900
3:196654645:TTG:T	donor_gain	0.9900
3:196654648:G:GG	donor_gain	0.9900
3:196654648:GT:G	donor_loss	0.9900

AlphaMissense

4493 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:196660422:A:T	N260I	0.996
3:196660344:G:T	S234I	0.995
3:196660423:C:A	N260K	0.995
3:196660423:C:G	N260K	0.995
3:196660216:C:A	N191K	0.994
3:196660216:C:G	N191K	0.994
3:196660288:C:A	N215K	0.994
3:196660288:C:G	N215K	0.994
3:196660413:T:C	L257P	0.994
3:196660350:A:T	N236I	0.993
3:196660351:C:A	N236K	0.993
3:196660351:C:G	N236K	0.993
3:196660421:A:T	N260Y	0.993
3:196660729:T:A	N362K	0.993
3:196660729:T:G	N362K	0.993
3:196660287:A:T	N215I	0.992
3:196660335:T:A	L231H	0.992
3:196660365:T:C	F241S	0.992
3:196660487:A:T	N282Y	0.991
3:196660488:A:T	N282I	0.991
3:196660489:C:A	N282K	0.991
3:196660489:C:G	N282K	0.991
3:196660657:C:A	N338K	0.991
3:196660657:C:G	N338K	0.991
3:196660144:C:A	N167K	0.990
3:196660144:C:G	N167K	0.990
3:196660335:T:C	L231P	0.990
3:196660272:T:C	L210P	0.989
3:196660349:A:T	N236Y	0.989
3:196660364:T:C	F241L	0.989

dbSNP variants (sampled 300 via entrez): RS1000012951 (3:196647514 A>T), RS1000070804 (3:196662470 C>T), RS1000173897 (3:196644698 C>T), RS1000211817 (3:196648869 C>T), RS1000250213 (3:196658865 G>A), RS1000261907 (3:196643235 C>G), RS1000371518 (3:196644927 G>C), RS1000483444 (3:196648174 A>G), RS1000505064 (3:196643458 A>G), RS1000613454 (3:196648690 C>T), RS1000705947 (3:196643699 A>G), RS1000759464 (3:196639104 T>G), RS1000832564 (3:196658104 C>T), RS1000902033 (3:196652773 T>C), RS1001100846 (3:196652998 T>G)

Disease associations

OMIM: gene MIM:615322 | disease phenotypes: MIM:618875

GenCC curated gene-disease

Disease	Classification	Inheritance
seizures, early-onset, with neurodegeneration and brain calcifications	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
seizures, early-onset, with neurodegeneration and brain calcifications	Definitive	AR

Mondo (1): seizures, early-onset, with neurodegeneration and brain calcifications (MONDO:0030033)

Orphanet (0):

HPO phenotypes

9 total (9 of 9 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0002059	Cerebral atrophy
HP:0002079	Hypoplasia of the corpus callosum
HP:0002188	Delayed CNS myelination
HP:0006970	Periventricular leukomalacia
HP:0008936	Axial hypotonia
HP:0012389	Appendicular hypotonia

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST004785_12	Vitiligo	3.000000e-08
GCST007564_1	Asthma or allergic disease (pleiotropy)	2.000000e-08
GCST008916_43	Asthma	4.000000e-15
GCST008916_55	Asthma	3.000000e-08
GCST009720_97	Asthma	3.000000e-11
GCST009798_34	Asthma	4.000000e-12
GCST010043_120	Asthma	2.000000e-16
GCST90002381_200	Eosinophil count	4.000000e-17
GCST90002382_589	Eosinophil percentage of white cells	2.000000e-18
GCST90014325_16	Asthma	5.000000e-16

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004842	eosinophil count
EFO:0007991	eosinophil percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
propionaldehyde	increases expression	1
HC toxin	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, decreases expression, affects response to substance	1
di-n-butylphosphoric acid	affects expression	1
oxamflatin	decreases expression	1
scriptaid	decreases expression	1
abrine	increases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Decitabine	increases expression	1
Panobinostat	decreases expression	1
Benzo(a)pyrene	decreases expression, decreases methylation, increases methylation	1
Cisplatin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Methyl Methanesulfonate	decreases expression	1
Oxygen	decreases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
S-Nitrosoglutathione	increases expression	1
Particulate Matter	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.